sb 239063 has been researched along with Sepsis in 1 studies
SB 239063: structure in first source
SB-239063 : A member of the class of imidazoles carrying 4-hydroxycyclohexyl, 4-fluorophenyl and 2-methoxypyrimidin-4-yl substituents at positions 1, 4 and 5 respectively.
Sepsis: Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, G | 1 |
| Zhang, Y | 1 |
| Liu, X | 1 |
| Fang, Q | 1 |
| Wang, Z | 1 |
| Fu, L | 1 |
| Liu, Z | 1 |
| Wang, Y | 1 |
| Zhao, Y | 1 |
| Li, X | 1 |
| Liang, G | 1 |
1 other study available for sb 239063 and Sepsis
| Article | Year |
|---|---|
Discovery of a New Inhibitor of Myeloid Differentiation 2 from Cinnamamide Derivatives with Anti-Inflammatory Activity in Sepsis and Acute Lung Injury.
Topics: Acute Lung Injury; Animals; Anti-Inflammatory Agents, Non-Steroidal; Binding Sites; Cinnamates; Cyto | 2016 |